SLU-PP-332

ERR pan-agonistNot a peptide · small moleculeMetabolic/Weight

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight

MechanismPan-agonist of the estrogen-related receptors ERRα/β/γ; induces the acute aerobic-exercise transcriptional programme in skeletal muscle in an ERRα-dependent way.

EffectsStudied as an "exercise mimetic". In mice, raised energy expenditure and fatty-acid oxidation, less fat-mass accumulation and improved insulin sensitivity.

DosingNo human dose established.

Bottom linePreclinical only — every published result is from mice.

Not a dose · what the literature contains instead

Rodent work used 30–50 mg/kg intraperitoneally twice daily for 12–28 days. There is no human pharmacokinetic data to scale from.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

Never given to a human in a registered trial. No safety, toxicity or pharmacokinetic data in people at any dose.

No human interaction data exists.

CV 2 of 5 — ERR pan-agonists improved cardiac fatty-acid metabolism and mitochondrial function in rodent heart-failure models. No human cardiovascular data.